Photo: Catalyst MedTech
March 25, 2026 — Catalyst MedTech, a provider of nuclear medicine and molecular imaging solutions, has announced it is continuing the national deployment of its Full Access Neurology solution — positioning the company as the definitive partner for implementing Brain PET imaging programs across the United States.
As momentum builds around biomarker-driven diagnosis in Alzheimer’s disease and other neurodegenerative conditions, the industry is reaching an inflection point. While new entrants and recent announcements highlight growing interest in dedicated brain imaging, the primary barrier remains unchanged: access to scalable, operational imaging solutions.
From Technology to Implementation
The emergence of dedicated Brain PET systems has reinforced what the industry already knows — advanced imaging is essential to diagnosis, therapy eligibility, and disease monitoring. However, technology alone does not solve the problem.
Catalyst MedTech’s Full Access Neurology solution is designed to operationalize Brain PET at scale — enabling neurology practices, health systems, imaging providers and clinical research sites to bring advanced imaging in-house without the traditional barriers of capital, staffing and infrastructure.
The platform integrates:
-
Optimized, dedicated Brain PET technology powered by CareMiBrain
-
Quantification and clinical workflow integration
-
Nationwide service, support, and maintenance
-
Flexible deployment models to enable rapid adoption
A Proven Model
Catalyst MedTech brings more than 26 years of experience implementing advanced imaging programs across nuclear cardiology — where the company has successfully expanded access nationwide through similar deployment models.
That same approach is now being applied to neurology.
Catalyst MedTech delivers a complete solution — combining equipment, service, clinical integration and operational support into a single, scalable model.
The Next Phase of Alzheimer’s Care
Recent developments, including the launch of dedicated Brain PET clinics in the U.S., reflect growing demand for infrastructure to support biomarker-driven diagnosis. These clinics are incorporating CareMiBrain, supported by Catalyst MedTech’s Full Access Neurology solution, to enable broader clinical adoption of optimized, dedicated Brain PET.
These developments underscore a critical shift - The market is no longer asking if Brain PET is needed—it is asking how to implement it.
Catalyst MedTech is answering that question.
Through Full Access Neurology, the company is enabling:
-
Earlier, more accurate diagnosis through biomarker-based imaging
-
Improved patient access to advanced diagnostic tools
-
Standardized imaging protocols for clinical care and research
-
Scalable infrastructure to support growing demand for neuroimaging
“Today’s neurology care is to be defined by equitable access to advanced imaging for earlier diagnosis and more confident care decisions across Alzheimer’s disease and other neurologic conditions, including Lewy body dementia, frontotemporal dementia, brain tumors, chronic traumatic encephalopathy (CTE), and psychiatric disorders,” said Martin Shirley, President and CEO at Catalyst MedTech. “The availability of FDG, amyloid-targeting agents, and emerging tau-targeting agents amplifies the need to create access through advanced technology, proven clinical models, and new workflows from a single source. At Catalyst MedTech, our 26-year track record has proven that innovation only matters when it reaches the people who need it. Through Full Access Neurology, we’re elevating Brain PET from a specialized resource to an accessible standard of care—giving patients and their care teams the insight required to make confident, timely decisions.”
For more information, please visit https://catalystmedtech.com/
March 30, 2026 
